Phase I study of definitive chemoradiotherapy with paclitaxel, CDDP and 5-FU (PCF-RT) for clinical stage IA-IIIC esophageal cancer
- Conditions
- esophageal cancer
- Registration Number
- JPRN-UMIN000028589
- Lead Sponsor
- Osaka international cancer institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 24
Not provided
1) Simultaneous or metachronous double cancers, with the exception of tumor curable with therapy before diagnosis of esophageal cancer 2) History of radiotherapy for mediastinum 3) Uncontrollable diabetes millutus 4) History of myocardial infarction within 6 months, or unstable angina pectoris or cardiac failure 5) Uncontrollable arrhythmia 6) Patients requiring systemic steroids medication 7) Liver cirrhosis 8) Active bacterial or fungous infection 9) With a history of grade 2-4 allergic reaction by CTCAE version 4.0 10) With grade 2-4 nerve disturbance by CTCAE version 4.0 11) With blood transfusion within 2 weeks and/or active bleeding 12) Interstitial pneumonia, fibroid lung or severe emphysema 13) With a history of allergic reaction to polyoxy-ethilen oil, hydrogenated castor oil or polysorbate 80 14) Psychosis 15) Pregnant or lactating women, women of childbearing potential or men who like to have children in future 16) Any patients judged by the investigator to be unfit to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method